Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Alana on +441494 818 020 or alana@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alana McKenna
Principal Account Manager
alana@zenopa.com
+441494 818 020

Testimonials
I would recommend Zenopa. I have dealt with around 30 different recruitment companies over the last 20 years and can say, hand on heart, Zenopa has stood out head and shoulders above the rest.
Will, 2013

Ark Therapeutics agrees University of Glasgow alliance

7 November 2011 00:00 in Medical Company Product News


Ark Therapeutics is entering into a new alliance with the University of Glasgow that will involve the provision of manufacturing services.

Under the terms of the deal, Ark will assist the university's institute of cardiovascular and medical sciences in the development of a gene therapy programme for treating vein graft failure associated with coronary artery bypass surgery.

The firm won an open competitive tender process to manufacture cGMP grade adenoviral vector-expressing TIMP3 genes, which will be administered ex vivo to vein grafts at the time of surgery in phase I/II trials.

According to the university, Ark was selected based on its experience in providing clinical grade reagents for medical applications.

Martyn Williams, chief executive officer of Ark, said: "Our success in this competitive tender exercise further demonstrates that Ark is establishing itself as a leading provider of viral manufacturing services utilising our world-leading expertise in this arena."

This comes after the firm announced a separate manufacturing partnership agreement with PsiOxus Therapeutics in September 2011.ADNFCR-8000103-ID-800788252-ADNFCR

Other news stories from 07/11/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd